Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to nipocalimab for treating adults with moderate-to-severe Sjögren’s …
FDA Grants Breakthrough Therapy Designation to Johnson & Johnson’s Nipocalimab for Sjögren’s Disease Read More
CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. has announced that its investigational therapy, NTX-001, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is poised to …
Neuraptive’s NTX-001 Secures Breakthrough Therapy Designation for Nerve Repair Read More
The U.S. Food and Drug Administration (FDA) recently approved Ogsiveo (nirogacestat) tablets for the systemic treatment of adult patients with progressing desmoid tumors, marking it as the first drug to …
FDA Approves Ogsiveo, First-Ever Drug for Treatment of Desmoid Tumors Read More
The Centers for Disease Control and Prevention (CDC) has recently announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg)), a long-acting monoclonal antibody designed to …
CDC Announces Release of Over 77,000 Additional Doses of Beyfortus™ for RSV Protection in Infants Read More